CTCFL and neoplasm: In conclusion, CTCFL-specific TCR 39.2E12CTCFL/KLH/A2 demonstrate anti-OVCA reactivity against (DAC-treated) CTCFL positive tumor cells without harming healthy cell subsets and is considered a promising TCR for TCR gene therapy of ovarian cancer.